[1] PRIORI S G,WILDE A A,HORIE M,et al. Executive summary:HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes[J].Heart Rhythm,2013,10(12):e85-e108.
[2] ROSTON T M,VINOCUR J M,MAGINOT K R,et al. Catecholaminergic poly-morphic ventricular tachycardia in children:analysis of therapeutic strategies and outcomes from an international multicenter registry[J]. Circ Arrhythm Electro physiol,2015,8(3):633-642.
[3] WLEKLINSKI M J,KANNANKEIL P J,KNOLLMANN B C. Molecular and tissue mechanisms of catecholaminergic ventricular tachycardia[J]. J Physiol,2020,598(14):2817-2834.
[4] VAN DERWERF C,NEDEREND I,HOFMAN N,et al. Familial evaluation in catechol-aminergic polymorphic ventricular tachycardia:disease penetrance and expression in cardiac ryanodine receptor mutation-carrying relatives[J]. Circ Arrhythm Electrophysiol,2012, 5(4):748-756.
[5] BALTOGIANNIS G G,LYSITSAS D N,DI GIOVANNI G,et al. CPVT: arrhythmogenesis,therapeutic management,and future perspectives. A Brief review of the literature[J]. Front Cardiovasc Med,2019,6:92.
[6] GONANO L A,JONES P P.FK506-binding proteins 12 and 12.6 (FKBPs) as regulators of cardiac ryanodine receptors: insights from new functional and structural knowledge[J].Channels(Austin),2017,11(5):415-425.
[7] RICHARDSON S J,THEKKEDAM C G,CASAROTTO M G ,et al. FKBP12 binds to the cardiac ryanodine receptor with negative cooperativity:implications for heart muscle physiology in health and disease[J]. Philos Trans R Soc Lond B Biol Sci,2023,378(1879): 20220169.
[8] WEGENER J W,WAGDI A,WAGNER E,et al. The RyR2-R2474S mutation sensitizes cardiomyocytes and hearts to catecholaminergic stress-induced oxidation of the mitochondrial glutathione pool[J].Front Physiol,2021,12:777770.
[9] 杨靖,张萍,吴寸草,等.儿茶酚胺敏感性多形性室性心动过速患者的平板运动试验特点分析[J].中国心血管杂志,2014,19(5):345-349.
[10] FUJITA S,NISHIDA K,IRABU H,et al. Catecholaminergic polymorphic ventricular tachycardia managed as orthostatic dysregulation and epilepsy in 11- and 15-year-old sisters[J]. Pediatr Int,2018,60(11): 998-1001.
[11] BROENDBERG A K,NIELSEN J C,BJERRE J,et al. Nationwide experience of catechol-aminergic polymorphic ventricular tachycardia caused by RyR2 mutations[J]. Heart,2017,103(12):901-909.
[12] SUMITOMO N,SAKURADA H,TANIGUCHI K,et al. Association of atrial arrhythmia and sinus node dysfunction in patients with catecholaminergic polymorphic ventricular tachycardia[J]. Circ J,2007, 71 (10):1606-1609.
[13] DI PINO A,CARUSO E,COSTANZO L,et al. A novel RyR2 mutation in a 2-year-old baby presenting with atrial fibrillation,atrial flutter,and atrial ectopic tachycardia[J]. Heart Rhythm,2014,11(8):1480-1483.
[14] BELLAMY D,NUTHALL G,DALZIEL S,et al. Catecholaminergic poly-morphic ventricular tachycardia: the cardiac arrest where epinephrine is contraindicated[J]. Pediatr Crit Care Med,2019,20(3):262-268.